FibroBiologics wins patent allowance for 3D spheroid wound therapy
FibroBiologics has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent covering its topical fibroblast spheroid therapy, in a development the company says directly reinforces the intellectual property position around its lead clinical programme.
The allowed application, US Patent Application No. 18/184,726, carries 19 claims directed at methods of treating and accelerating wound healing by topically administering compositions of three-dimensional (3D) spheroid fibroblasts, either alone or combined with fibroblast-derived materials such as exosomes and extracellular vesicles. A Notice of Allowance means the USPTO has completed examination and intends to grant the patent; formal issuance follows payment of issue fees.
The clinical connection
The timing is significant because FibroBiologics is currently running a Phase 1/2 clinical trial of CYWC628, an investigational allogeneic fibroblast-spheroid cell-based therapy applied topically to diabetic foot ulcers. The allowed claims explicitly cover the treatment of chronic wounds in patients with diabetes, which maps precisely onto the CYWC628 trial population.
Pete O'Heeron, founder and chief executive, said the allowance "protects the very approach we are now advancing in the clinic" and strengthens the company's competitive position as clinical data accumulates. Chief scientific officer Hamid Khoja noted that the USPTO examiner had specifically recognised the 3D spheroid and fibroblast-derived material combination as not taught by prior art, which the company considers the core differentiator of its wound care platform.
FibroBiologics, listed on Nasdaq under the ticker FBLG and headquartered in Houston, describes a portfolio of more than 270 issued and pending US and international patents spanning wound healing, multiple sclerosis, disc degeneration, psoriasis and oncology.
Market context and competitive landscape
Diabetic foot ulcers represent one of the most commercially significant segments within the chronic wound care market. Standard-of-care options include growth-factor dressings, bioengineered skin substitutes and, increasingly, platelet-rich plasma approaches, but healing rates in complex or infected ulcers remain poor. Amputation risk gives the segment a high unmet need profile that attracts both specialist developers and larger medical-device companies with wound care divisions.
Cell-based therapies for wound healing sit at the intersection of cell and gene therapy and conventional wound management. Several companies are advancing allogeneic cell products, including fibroblast-based and keratinocyte-based constructs, though the field has seen regulatory complexity around the classification of such products by both the FDA and the EMA. The FDA's Centre for Biologics Evaluation and Research has jurisdiction over cell therapy wound products, and manufacturers typically must navigate a biologics licence application pathway rather than a 510(k) or PMA route. FibroBiologics has not disclosed a target BLA filing date, and the Phase 1/2 trial is focused primarily on safety and preliminary efficacy signals rather than pivotal endpoints.
Securing granted claims that align directly with an active clinical programme can assist in out-licensing discussions and partnership negotiations, giving potential counterparties a clearer picture of the exclusivity FibroBiologics could offer in any deal. The company has not announced a commercial partner for CYWC628 to date.